Sunshine Lake Pharma Co., Ltd.

Guangdong Oppo Mobile Telecommunications Corp., Ltd.

North & South Brother Pharmacy Investment Company Limited

Bing Liu

Yingjun Zhang

Changchung Cheng

Jiancun Zhang

Wei Zhang

Xiaohui Wang

Yimei Tang

Yi Sun

Hong Zou

Xinfeng Liao

Zhiqin Hu

Yuchu Xu

Weihong Zhang

Jinlei Liu

Yong Li

Wei Feng Chen

Wei Chen

Lu Zhang

Yong Min Li

Liang Chen

Jiquan Zhang

Yu Chen

Tianzhu Yu

Bohua Long

Zhixin Cheng

Xiangyu Zhang

Chengxi Li

Shiguo Zhang

Linlin Nie

Shun Bai

Mingyu Guan

Xuke Li

A salt of a substituted urea derivative of formula (I) and use thereof in the pharmaceutical field. Also, a pharmaceutical composition containing the salt or a combination thereof, and use of the salt or the pharmaceutical composition in the manufacture of a medicament for treating, remitting or preventing a disorder related to tyrosine kinase activity. 

Salt of substituted urea derivative and use thereof in medicine

A front cover assembly includes a frame, a cover glass, and a waterproof glue. The frame has a receiving cavity. The cover glass is partially received in the frame. The cover glass has a lateral face facing the frame. The cover glass has a step portion located at the lateral face. A first gap is defined between a first face of the step portion of the cover glass and a first wall of the frame, and a second gap is defined between a second face of the step portion of the cover glass and a second wall of the frame. A waterproof glue fills the first and second gaps. The first and second faces of the step portion from an obtuse angle therebetween, which faces the first and second walls of the frame. The present disclosure also relates to a terminal.

Front cover assembly and terminal

The invention relates to a salt, a hydrate or a crystalline form of an EGFR inhibitor, and use thereof. Specifically it relates to 4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-[3-[(1R,6S)-2,5-dioxa-8-azabicyclo [4.3.0] nonan-8-yl] propoxy] quinazoline dimethanesulfonate, hydrate and a crystalline form thereof; the invention also relates to a preparation method of the crystalline form disclosed herein, a pharmaceutical composition containing the crystalline form, and uses thereof for treating proliferative disorders.

Salt of EGFR inhibitor, crystalline form and uses thereof

A front cover assembly includes a frame, a cover glass, and a waterproof glue. The frame has a receiving cavity. The cover glass is partially received in the frame. The cover glass has a light exiting face and a lateral face extending from the light exiting face. The cover glass has a step portion located at the lateral face and extending toward the frame. A gap is defined between the step portion of the cover glass and the frame. A waterproof glue fills the gap and directly contacts the step portion and the frame. This assembly can prevent water or dust from entering a terminal device.

Provided herein are novel substituted urea derivatives, and pharmaceutical compositions thereof. Also provided herein are uses of the compounds or pharmaceutical compositions thereof for preventing, managing, treating or lessening a proliferative disease, and modulating the activity of protein kinase.

Substituted urea derivatives and pharmaceutical uses thereof

The compounds of Formula (I) which can be used as CRTH2 receptor antagonists are provided. The compounds of Formula (I) can be used in the treatment and prevention of asthma, allergic rhinitis and atopic dermatitis, as well as other diseases mediated by prostaglandin D2 (PGD2) at the CRTH2 receptor. 

Compounds as CRTH2 antagonist and uses thereof

The invention provides compounds as CDK small-molecule inhibitors and uses thereof, the compounds can be used for treating inflammation and cell proliferation diseases. The novel compound of the invention is a powerful cyclin-dependent kinase 4 (CDK 4) or cyclin-dependent kinase-6 (CDK 6) inhibitor.

2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof

Provided herein are aminoquinazoline compounds, salts and uses thereof. The compounds have Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. Also provided herein are pharmaceutical compositions containing the compounds disclosed herein, and uses of the compounds or the compositions for preventing, managing, treating or lessening the severity of a proliferative disorder in a patient and for modulating the protein tyrosine kinase activity. 

Aminoquinazoline derivatives and their salts and methods of use thereof

The present invention relates to the field of medicine. Provided herein are aminoquinazoline derivatives, their salts and pharmaceutical formulations useful in modulating the protein tyrosine kinase activity, and in modulating inter- and/or intra-cellular signaling. Also provided herein are pharmaceutically acceptable compositions comprising the aminoquinazoline compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

Aminoquinazoline derivatives and their salts and methods of use

Growing community of inventors

Dongguan, China

Bing Liu